In STEMI with cardiogenic shock, should Impella CP be used routinely based on DanGer-SHOCK, or restricted to patients resembling the trial's selected population?

Active since Apr 2024

Heat

Patients affected

Resolution

No fixed date yet

Sources

How this gets settled

Resolution

No fixed date yet

What settles itShared decision-making + role clarity

The debate

Use it routinelyvsReserve for selected patients

Who could settle it

Know an expert who could settle this? Suggest one →

Who could fund or run it

Academia

Funders

Industry

Institutions that could fund, run, or adopt

Who this affects

Affected rangeEstimate

0–0

disputed 23.6% in the Impella CP group vs. 12.1% in the control group

Get involved

Preview

JEDJGAKFMK

Not yet tracked

WatchSteer thisSoon

Sources & verification

30linked & dated sources

VerifiedConfirmed against a primary source (registry API or dual-model citation gate).EstimateA computed estimate (e.g. comparable-based cost or modeled range), not a measured value.Scan-reportedReported by the scan and linked to its source — not yet independently verified.